Literature DB >> 21187585

Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease.

Matthew Schrag1, Andrew Crofton, Matthew Zabel, Arshad Jiffry, David Kirsch, April Dickson, Xiao Wen Mao, Harry V Vinters, Dylan W Domaille, Christopher J Chang, Wolff Kirsch.   

Abstract

Cerebral amyloid angiopathy (CAA) is a vascular lesion associated with Alzheimer's disease (AD) present in up to 95% of AD patients and produces MRI-detectable microbleeds in many of these patients. It is possible that CAA-related microbleeding is a source of pathological iron in the AD brain. Because the homeostasis of copper, iron, and zinc are so intimately linked, we determined whether CAA contributes to changes in the brain levels of these metals. We obtained brain tissue from AD patients with severe CAA to compare to AD patients without evidence of vascular amyloid-β. Patients with severe CAA had significantly higher non-heme iron levels. Histologically, iron was deposited in the walls of large CAA-affected vessels. Zinc levels were significantly elevated in grey matter in both the CAA and non-CAA AD tissue, but no vascular staining was noted in CAA cases. Copper levels were decreased in both CAA and non-CAA AD tissues and copper was found to be prominently deposited on the vasculature in CAA. Together, these findings demonstrate that CAA is a significant variable affecting transition metals in AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21187585      PMCID: PMC4507570          DOI: 10.3233/JAD-2010-101503

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  64 in total

1.  Imaging metals in proteins by combining electrophoresis with rapid x-ray fluorescence mapping.

Authors:  Lydia Finney; Yasmin Chishti; Tripti Khare; Carol Giometti; Aviva Levina; Peter A Lay; Stefan Vogt
Journal:  ACS Chem Biol       Date:  2010-06-18       Impact factor: 5.100

2.  Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias.

Authors:  Shino Magaki; Ravi Raghavan; Claudius Mueller; Kerby C Oberg; Harry V Vinters; Wolff M Kirsch
Journal:  Neurosci Lett       Date:  2007-03-03       Impact factor: 3.046

3.  Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Authors:  Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Stellan Batsman; David Ames; John Harrison; Colin L Masters; Steve Targum; Ashley I Bush; Ross Murdoch; Janet Wilson; Craig W Ritchie
Journal:  Lancet Neurol       Date:  2008-07-30       Impact factor: 44.182

4.  Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin.

Authors:  W A Jefferies; M R Food; R Gabathuler; S Rothenberger; T Yamada; O Yasuhara; P L McGeer
Journal:  Brain Res       Date:  1996-03-11       Impact factor: 3.252

5.  Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex.

Authors:  Karen M Cullen; Zoltán Kócsi; Jonathan Stone
Journal:  J Cereb Blood Flow Metab       Date:  2005-12       Impact factor: 6.200

6.  Imaging of the intracellular topography of copper with a fluorescent sensor and by synchrotron x-ray fluorescence microscopy.

Authors:  Liuchun Yang; Reagan McRae; Maged M Henary; Raxit Patel; Barry Lai; Stefan Vogt; Christoph J Fahrni
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

7.  Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions.

Authors:  D A Loeffler; J R Connor; P L Juneau; B S Snyder; L Kanaley; A J DeMaggio; H Nguyen; C M Brickman; P A LeWitt
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

8.  Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease.

Authors:  Avi L Friedlich; Joo-Yong Lee; Thomas van Groen; Robert A Cherny; Irene Volitakis; Toby B Cole; Richard D Palmiter; Jae-Young Koh; Ashley I Bush
Journal:  J Neurosci       Date:  2004-03-31       Impact factor: 6.167

9.  Brain Iron and Zinc Contents of German Patients with Alzheimer Disease.

Authors:  Erzsébet Andrási; Eva Farkas; Dieter Gawlik; Ullrich Rösick; Peter Brätter
Journal:  J Alzheimers Dis       Date:  2000-03       Impact factor: 4.472

Review 10.  Brain parenchymal and microvascular amyloid in Alzheimer's disease.

Authors:  H V Vinters; Z Z Wang; D L Secor
Journal:  Brain Pathol       Date:  1996-04       Impact factor: 6.508

View more
  20 in total

1.  Selective, quantitative measurement of releasable synaptic zinc in human autopsy hippocampal brain tissue from Alzheimer's disease patients.

Authors:  Nicole L Bjorklund; V-M Sadagoparamanujam; Giulio Taglialatela
Journal:  J Neurosci Methods       Date:  2011-09-16       Impact factor: 2.390

Review 2.  Neuropsychological Effects of Cerebral Amyloid Angiopathy.

Authors:  Matthew Schrag; Howard Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2016-08       Impact factor: 5.081

3.  Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion.

Authors:  Matthew Schrag; Claudius Mueller; Udochukwu Oyoyo; Mark A Smith; Wolff M Kirsch
Journal:  Prog Neurobiol       Date:  2011-05-11       Impact factor: 11.685

Review 4.  Atypical Clinical Manifestations of Cerebral Amyloid Angiopathy.

Authors:  Carolyn Akers; Lealani May Y Acosta; Ciaran Considine; Daniel Claassen; Howard Kirshner; Matthew Schrag
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-27       Impact factor: 5.081

5.  Considering the vascular hypothesis of Alzheimer's disease: effect of copper associated amyloid on red blood cells.

Authors:  Heather R Lucas; Joseph M Rifkind
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 6.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

7.  Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment.

Authors:  Claudius Mueller; Matthew Schrag; Andrew Crofton; Jens Stolte; Martina U Muckenthaler; Shino Magaki; Wolff Kirsch
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 8.  Biometals and their therapeutic implications in Alzheimer's disease.

Authors:  Scott Ayton; Peng Lei; Ashley I Bush
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

9.  Zinc and the aging brain.

Authors:  Johnathan R Nuttall; Patricia I Oteiza
Journal:  Genes Nutr       Date:  2013-12-24       Impact factor: 5.523

Review 10.  The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin.

Authors:  Douglas G Peters; James R Connor; Mark D Meadowcroft
Journal:  Neurobiol Dis       Date:  2015-08-22       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.